Stopping treatment after pregnancy

Published: 01 June 2012

Where a woman does not yet require HIV treatment for her own health, a short-term combination of drugs can be prescribed during pregnancy to reduce transmission risk, without compromising her own future treatment options.

However, if nevirapine (Viramune) or efavirenz (Sustiva) have been used in her treatment, stopping their use will need to be carefully planned to allow for their long half-lives (the half-life of a drug is the period for which it is active) to avoid inadvertent NNRTI monotherapy and the chance that resistance will develop.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.